These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 8305535)
21. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768 [TBL] [Abstract][Full Text] [Related]
22. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives. Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027 [TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Zunino F; Capranico G Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303 [TBL] [Abstract][Full Text] [Related]
24. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822 [TBL] [Abstract][Full Text] [Related]
25. A model for tumor cell killing by topoisomerase poisons. Zhang H; D'Arpa P; Liu LF Cancer Cells; 1990 Jan; 2(1):23-7. PubMed ID: 2167111 [TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310 [TBL] [Abstract][Full Text] [Related]
27. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Meikle I; Cummings J; Macpherson JS; Smyth JF Anticancer Drug Des; 1995 Oct; 10(7):515-27. PubMed ID: 7495476 [TBL] [Abstract][Full Text] [Related]
28. [Inhibition by ellipticine derivatives of the reactions catalysed by the topoisomerases: preferential inhibition of topoisomerase II]. Douc-Rasy S; Multon E; Kayser A; Riou G C R Seances Acad Sci III; 1983; 296(19):899-904. PubMed ID: 6311366 [TBL] [Abstract][Full Text] [Related]
29. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Cline SD; Macdonald TL; Osheroff N Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action. Gopal YN; Jayaraju D; Kondapi AK Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357 [TBL] [Abstract][Full Text] [Related]
31. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Ross W; Rowe T; Glisson B; Yalowich J; Liu L Cancer Res; 1984 Dec; 44(12 Pt 1):5857-60. PubMed ID: 6094001 [TBL] [Abstract][Full Text] [Related]
32. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987 [TBL] [Abstract][Full Text] [Related]
33. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Kobayashi Y; Yamashita Y; Fujii N; Takaboshi K; Kawakami T; Kawamura M; Mizukami T; Nakano H Planta Med; 1995 Oct; 61(5):414-8. PubMed ID: 7480201 [TBL] [Abstract][Full Text] [Related]
34. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus]. René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795 [TBL] [Abstract][Full Text] [Related]
35. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Bromberg KD; Burgin AB; Osheroff N Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542 [TBL] [Abstract][Full Text] [Related]
36. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542 [TBL] [Abstract][Full Text] [Related]
37. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors. Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406 [TBL] [Abstract][Full Text] [Related]
38. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094 [TBL] [Abstract][Full Text] [Related]
39. Multilevel therapeutic targeting by topoisomerase inhibitors. Smith PJ; Souès S Br J Cancer Suppl; 1994 Sep; 23():S47-51. PubMed ID: 8075006 [TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Beere HM; Chresta CM; Hickman JA Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]